Vaxcyte's VAX-31 Phase 1/2 Data Published in Lancet, Demonstrating Superiority to PCV20 for Key Serotypes
Summary
Vaxcyte announced the publication of positive Phase 1/2 adult clinical trial data for its lead 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in The Lancet Infectious Diseases. The study demonstrated VAX-31 was well-tolerated with a safety profile similar to Prevnar 20® (PCV20) and elicited robust immune responses across all 31 serotypes. Critically, the data showed superiority to PCV20 for 11 incremental serotypes unique to VAX-31 and greater immune responses for 18 of 20 serotypes common with PCV20, with seven achieving statistical significance. This publication provides significant validation and de-risking for VAX-31, reinforcing its 'best-in-class potential' and competitive advantages over existing standard-of-care vaccines. For a clinical-stage biotech, strong positive data published in a top-tier journal is a major catalyst that can significantly enhance investor confidence and the drug's commercial outlook. Investors will now focus on the upcoming topline data from the OPUS-1 pivotal noninferiority Phase 3 trial, expected in the fourth quarter of 2026, which will be crucial for supporting a Biologics License Application.
At the time of this announcement, PCVX was trading at $54.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $27.66 to $76.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.